Biogen Inc. (BIIB) income statement
NASDAQ · Healthcare · Drug Manufacturers - General · 7,500 employees · CEO Christopher A. Viehbacher
- Price
- $253.62 +1.59%
- Market cap
- $37.5B
- Enterprise value
- $44B
- Last report
- Q3 '26 filed 2026-10-28
- Next report
- 2027-02-05 EPS est. $2.85
Biogen Inc. (BIIB) reported revenue of $2.8B for Q3 '26 (+14.2% year on year), operating income of $128M (4.6% of revenue) and net income of -$20.6M. Over the last four quarters revenue was $10.3B.
Income statement
| Income statement | Trend | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.39B | $2.29B | $2.46B | $2.47B | $2.45B | $2.43B | $2.65B | $2.45B | $2.28B | $2.48B | $2.74B | $2.8B | |
| Cost of revenue | $618M | $498M | $956M | $639M | $584M | $578M | $946M | $877M | $496M | $661M | $1.18B | $748M | |
| Gross profit | $1.77B | $1.79B | $1.51B | $1.83B | $1.87B | $1.85B | $1.7B | $1.58B | $1.78B | $1.82B | $1.56B | $2.06B | |
| Research & development | $648M | $524M | $592M | $673M | $684M | $546M | $530M | $370M | $509M | $573M | $496M | $574M | |
| Sales & marketing | $71.4M | $0 | $0 | $0 | $66.8M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| General & administrative | $537M | $0 | $0 | $0 | $612M | $0 | $0 | $0 | $683M | $0 | $0 | $752M | |
| Other operating expenses | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $648M | $239M | $34M | $601M | |
| Operating expenses | $1.26B | $1.1B | $1.14B | $1.25B | $1.36B | $1.12B | $1.11B | $964M | $1.84B | $1.42B | $1.24B | $1.93B | |
| Operating income | $512M | $690M | $367M | $577M | $509M | $733M | $588M | $614M | -$57M | $397M | $318M | $128M | |
| Interest income | $23.8M | $17.4M | $20.1M | $11.6M | $18.5M | $23.9M | $32.3M | $31.6M | $37.2M | $37.9M | $25.3M | $9.3M | |
| Interest expense | $71.5M | $69.2M | $61.3M | $59.8M | $60M | $60M | $72.6M | $67.4M | $67.5M | $67.6M | $82.3M | $87.5M | |
| Other non-operating income (gains on investments, FX ...) | $51.3M | $58M | -$443M | $45.6M | $1.3M | $50.7M | -$328M | -$10.9M | $86.5M | -$19.7M | $103M | $49.9M | |
| Total non-operating income | -$221M | -$226M | $332M | -$126M | -$218M | -$421M | $156M | -$56.5M | -$154M | -$19.7M | -$186M | -$137M | |
| Income before tax | $292M | $465M | $699M | $451M | $292M | $311M | $744M | $557M | -$211M | $378M | $132M | -$9M | |
| Income tax | $42.7M | $71.4M | $115M | $62.5M | $24.8M | $70.7M | $109M | $90.8M | -$163M | $58.2M | $34.9M | $11.6M | |
| Net income | $250M | $393M | $584M | $389M | $267M | $241M | $635M | $467M | -$48.4M | $320M | $97.5M | -$20.6M | |
| EPS (basic) | $1.72 | $2.71 | $4.01 | $2.67 | $1.83 | $1.65 | $4.35 | $3.18 | -$0.33 | $2.17 | $0.66 | -$0.14 | |
| EPS (diluted) | $1.71 | $2.70 | $4.00 | $2.66 | $1.83 | $1.64 | $4.35 | $3.17 | -$0.33 | $2.15 | $0.66 | -$0.14 | |
| Shares (basic, weighted) | 145M | 145M | 146M | 146M | 146M | 146M | 146M | 147M | 147M | 147M | 148M | 148M | |
| Shares (diluted, weighted) | 146M | 146M | 146M | 146M | 146M | 146M | 146M | 147M | 147M | 148M | 149M | 148M | |
| Depreciation & amortization | $140M | $148M | $159M | $183M | $184M | $183M | $194M | $202M | $200M | $204M | $236M | $241M | |
| EBITDA | $601M | $780M | $968M | $714M | $692M | $865M | $1.11B | $827M | $56.7M | $622M | $451M | $320M |
| Income statement | Trend | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11.4B | $12.3B | $13.5B | $14.4B | $13.4B | $11B | $10.2B | $9.84B | $9.68B | $9.81B | |
| Cost of revenue | $1.43B | $1.63B | $1.82B | $1.96B | $1.81B | $2.11B | $2.28B | $2.53B | $2.31B | $2.9B | |
| Gross profit | $10B | $10.6B | $11.6B | $12.4B | $11.6B | $8.87B | $7.9B | $7.3B | $7.37B | $6.91B | |
| Research & development | $1.97B | $2.37B | $2.71B | $2.77B | $4.53B | $3.4B | $2.6B | $2.7B | $2.49B | $1.95B | |
| Sales & marketing | $106M | $75.2M | $90.2M | $79.2M | $112M | $98.7M | $54.1M | $71.4M | $66.8M | $0 | |
| General & administrative | $1.84B | $1.86B | $2.02B | $2.28B | $2.4B | $2.58B | $2.35B | $2.43B | $2.32B | $2.43B | |
| Other operating expenses | $941M | $988M | $929M | $251M | $0 | $0 | $0 | $0 | $0 | $648M | |
| Operating expenses | $4.86B | $5.3B | $5.75B | $5.38B | $7.05B | $6.08B | $5.01B | $5.2B | $4.88B | $5.04B | |
| Operating income | $5.15B | $5.35B | $5.89B | $7.04B | $4.59B | $2.79B | $2.89B | $2.1B | $2.49B | $1.88B | |
| Interest income | $63.4M | $78.5M | $113M | $120M | $42M | $11M | $89.3M | $277M | $67.6M | $87.8M | |
| Interest expense | $260M | $251M | $201M | $187M | $223M | $254M | $247M | $247M | $250M | $246M | |
| Other non-operating income (gains on investments, FX ...) | -$557M | -$541M | -$476M | -$233M | -$58.1M | -$644M | -$129M | $215M | $168M | -$288M | |
| Total non-operating income | -$219M | -$217M | $11M | $3.9M | $460M | -$1.01B | $705M | -$801M | -$584M | -$476M | |
| Income before tax | $4.93B | $5.13B | $5.9B | $7.05B | $5.05B | $1.78B | $3.59B | $1.3B | $1.91B | $1.4B | |
| Income tax | $1.24B | $2.46B | $1.43B | $1.16B | $992M | $52.5M | $633M | $135M | $274M | $108M | |
| Net income | $3.7B | $2.54B | $4.43B | $5.89B | $4B | $1.56B | $3.05B | $1.16B | $1.63B | $1.29B | |
| EPS (basic) | $16.96 | $11.94 | $21.62 | $31.47 | $24.86 | $10.44 | $20.97 | $8.02 | $11.20 | $8.85 | |
| EPS (diluted) | $16.93 | $11.92 | $21.58 | $31.42 | $24.80 | $10.40 | $20.87 | $7.97 | $11.19 | $8.83 | |
| Shares (basic, weighted) | 218M | 213M | 205M | 187M | 161M | 149M | 145M | 145M | 146M | 147M | |
| Shares (diluted, weighted) | 219M | 213M | 205M | 187M | 161M | 150M | 146M | 146M | 146M | 147M | |
| Depreciation & amortization | $683M | $722M | $651M | $465M | $457M | $488M | $518M | $495M | $673M | $780M | |
| EBITDA | $6.39B | $6.61B | $7.01B | $7.74B | $5.11B | $3.92B | $3.54B | $2.38B | $3B | $2.95B |
Standardised by Financial Modeling Prep from the company's filings; outflows and costs keep the sign the provider reports. Hover a period for its end date. Amounts in USD.
Revenue, operating income and growth
quarterlyMargins
quarterlyCosts as % of revenue
quarterlyThe other statements
Sources
Statements, segment revenue, metrics, estimates: Financial Modeling Prep. Segment profits and every reported line: SEC EDGAR (XBRL). Filings read: 10-Q 2026-09-30, 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30
Data as of 2026-11-02